CFDE Data Portal | Search SLC9A3-OT1

	Label	Description
	SLC9A3-OT1 Gene (Entity type)	ENSG00000188242 - SLC9A3 3' UTR overlapping transcript 1
	GSE120612 etoposide leukocyte 6 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE197555 0 V 3 TRAMETINIB HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE261563 CX-5461 6 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE216273 GSE216292 palbociclib 14 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE120612 4 V 1 ETOPOSIDE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE101239 5 V 6 VALPROIC ACID MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE238213 dopamine 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE248769 1 V 0 SORAFENIB HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE187006 3 V 2 VALPROIC ACID HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS

SLC9A3-OT1

ENSG00000188242 - SLC9A3 3' UTR overlapping transcript 1

GSE120612 etoposide leukocyte 6 v 1 human up

A Gene Set from LINCS

GSE197555 0 V 3 TRAMETINIB HUMAN UP

A Gene Set from LINCS

GSE261563 CX-5461 6 v 1 human up

A Gene Set from LINCS

GSE216273 GSE216292 palbociclib 14 v 1 human dn

A Gene Set from LINCS

GSE120612 4 V 1 ETOPOSIDE HUMAN UP

A Gene Set from LINCS

GSE101239 5 V 6 VALPROIC ACID MOUSE UP

A Gene Set from LINCS

GSE238213 dopamine 1 v 0 human dn

A Gene Set from LINCS

GSE248769 1 V 0 SORAFENIB HUMAN UP

A Gene Set from LINCS

GSE187006 3 V 2 VALPROIC ACID HUMAN UP

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.